LAL deficiency patient registry
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study keeps a protected record of people with Lysosomal Acid Lipase (LAL) deficiency to learn more about the condition over time. It may help researchers better understand how patients are doing and support future studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of LAL deficiency
- You (or your legal representative) must sign consent to join, or have consent waived if approved
- You cannot be enrolled in an Alexion-sponsored clinical trial right now
- If you previously took part in an Alexion sebelipase alfa study, you can enroll in this registry
- Joining this registry will not stop you from joining a future clinical trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a registry that collects information from people diagnosed with lysosomal storage diseases. It helps researchers better understand these conditions and support future studies.
This is a study that keeps a medical record (a registry) of people with lipodystrophy, a condition where body fat is missing or unevenly distributed. It may help researchers understand different causes and patterns of the condition over time.
This study builds a national registry to better understand adrenoleukodystrophy (ALD) in patients and families. You may help researchers learn how ALD affects people over time and improve future care.
This trial tests a new method called LILAC to help people learn about and manage high levels of lipoprotein(a), a type of fat in the blood. It is for anyone 16 or older who attends educational events or is part of a health group.
This is a registry study that collects health information from people diagnosed with neutral lipid storage disease (NLSD) or triglyceride deposit cardiomyovasculopathy (TGCV). It may help researchers better understand the condition and improve future care plans.
This study tracks people with LCAT deficiency over time to learn more about how the condition affects the body. It does not test a treatment, but helps researchers understand the disease better so they can design future studies.
Hear when a new Wolman Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.